Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Aricept

Aricept
In stock
5mg · 10mg
from A$54.91
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$65.90A$54.91
A$1.83 per tablet

In brief

  • Available from community pharmacies and online suppliers; Aricept (donepezil) is officially prescription-only (Rx) in Australia and most countries, though some pharmacies or online vendors may offer it without a prescription — this is not recommended and may be unsafe.
  • Aricept is used to treat symptoms of Alzheimer’s disease (mild, moderate and severe) and is a central cholinesterase inhibitor: it increases acetylcholine levels by inhibiting acetylcholinesterase, producing symptomatic cognitive and functional benefits for some patients (it is not a cure).
  • Usual dosing starts at 5 mg once daily; after 4–6 weeks may increase to 10 mg once daily for mild–moderate disease. For moderate–severe disease, treatment can start at 5 mg then 10 mg, and after ≥3 months on 10 mg may be increased to 23 mg once daily; the maximum licensed dose is 23 mg daily.
  • Administered orally as tablets or orally disintegrating tablets (5 mg, 10 mg, and 23 mg formulations available in many markets); a transdermal patch formulation (Adlarity) is available in some countries (US). No injectable forms are available.
  • Clinical effects may begin to appear within 1–4 weeks for some cognitive or behavioural symptoms, with more noticeable benefit often seen after 4–6 weeks and following dose adjustments.
  • Pharmacological effect is maintained with once-daily dosing (symptomatic coverage over 24 hours); donepezil has a long elimination half-life (around 60–70 hours), so steady effects are sustained with daily use and treatment is chronic.
  • Avoid excessive alcohol while taking Aricept; alcohol can worsen dizziness, sedation, cognitive impairment and gastrointestinal side effects and may increase risk of falls.
  • The most common side effect is nausea (and other gastrointestinal symptoms such as diarrhoea, vomiting and appetite loss); other frequent effects include insomnia, vivid dreams, fatigue, dizziness and muscle cramps; serious risks include bradycardia and GI bleeding in at-risk patients.
  • Would you like to try aricept without a prescription?

Basic Aricept Information

  • INN (International Nonproprietary Name): Donepezil (also referred to as donepezilum in Eastern Europe).
  • Brand Names Available In Australia: Aricept (originator); local generic suppliers not specified in RAW_DATA — Aricept and generic donepezil are widely marketed globally in 5 mg, 10 mg and 23 mg formulations.
  • ATC Code: N06DA02 — Donepezil (Cholinesterase Inhibitor).
  • Forms & Dosages: Tablets 5 mg, 10 mg, 23 mg; Orally Disintegrating Tablets (ODT) 5 mg, 10 mg; transdermal patch forms (Adlarity) marketed in the US — no parenteral forms available.
  • Manufacturers In Australia: not specified in RAW_DATA (global manufacturers include Eisai, Pfizer, Teva, Sandoz, Mylan, Zentiva, Alvogen).
  • Registration Status In Australia: Status not specified by country in RAW_DATA, but donepezil is prescription-only (Rx) in all jurisdictions per RAW_DATA.
  • OTC / Rx Classification: Prescription-only (Rx).

Critical Warnings, Restrictions And Patient Protection (Australia)

High-Risk Groups (Elderly, Pregnancy, Chronic Illness)

  • Prescription status: Donepezil (INN: donepezil, ATC N06DA02) is prescription-only.
  • Absolute contraindication: Known hypersensitivity to donepezil hydrochloride or piperidine derivatives.
  • Severe liver impairment: Use with caution in severe liver disease.
  • Elderly: Main treatment group; monitor for bradycardia and atrioventricular block — cardiac monitoring advised before and during treatment.
  • Respiratory disease: Patients with asthma or COPD require risk–benefit review due to potential bronchospasm risk.
  • Gastrointestinal disease: History of peptic ulcer or GI bleeding increases risk with cholinesterase inhibitors; review NSAID use.
  • Seizure disorders: Exercise caution where seizure history exists.
  • Urinary / Prostatic issues: Urinary retention or prostatic hypertrophy may worsen; review bladder symptoms prior to prescribing.

Checklist For Prescribers/Pharmacists:

  • Review current medicines with special attention to beta-blockers, digoxin and NSAIDs.
  • Record baseline pulse and blood pressure before starting treatment.
  • Assess gastrointestinal bleed risk and history of ulcers.
  • Establish a cognitive baseline and document treatment goals and expected benefits.
  • Confirm advance care directives and involve carers in monitoring plans.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Concern: Will donepezil affect my ability to drive or work safely?

  • Donepezil may cause dizziness, drowsiness, blurred vision or syncope in some patients.
  • Advise patients not to drive or operate heavy machinery until they know how the medicine affects them.
  • Employers and clinicians should assess fitness-for-work where cognitive impairment or medication side effects impair safety-sensitive tasks.

Legal Note:

  • Driving fitness and reporting requirements are assessed according to each Australian state and territory guideline.
  • Clinicians should advise patients to notify licensing authorities if side effects impair driving and if local rules require it.

Patient Checklist:

  • Monitor for dizziness, fainting or marked drowsiness during the first 2–6 weeks.
  • Keep a record of any fainting, syncope or near-miss episodes and report them to your GP or pharmacist.
  • Avoid alcohol until tolerability is established as alcohol can worsen dizziness and sedation.

Q&A — “Can I Drive After Taking It In Australia?”

Q: Can I drive after taking donepezil (Aricept)?

A: Not until you know how it affects you.

If you experience dizziness, fainting, marked drowsiness or visual changes, don’t drive and seek medical advice.

Document episodes and follow your state driving fitness rules; discuss with your GP or treating specialist.

Usage Basics: INN, Brands And Legal Classification In Australia

INN And Brand Names Available (Australian Context)

What names will patients recognise when asking for this medicine?

  • INN: Donepezil (sometimes listed as donepezilum in Eastern Europe).
  • Originator brand: Aricept (Eisai/Pfizer) — commonly packaged in 5 mg, 10 mg and 23 mg tablets.
  • ODT and patches: Orally disintegrating tablets (5 mg, 10 mg) are marketed globally; transdermal patches (Adlarity) are available in the US.

Common Formulations To Stock In Community Pharmacy:

  • Tablets: Donepezil 5 mg and 10 mg (standard starter and maintenance strengths).
  • Tablets: Donepezil 23 mg (for selected moderate–severe cases following escalation).
  • ODT: Donepezil ODT 5 mg and 10 mg (for patients with swallowing difficulties where available).
  • Patch: Adlarity patch (5 mg/10 mg) noted in US markets — availability in Australia not specified in RAW_DATA.

Table Placeholder: Common Formulations To Stock

Legal Classification (TGA Approval, PBS Listing)

  • Donepezil is prescription-only (Rx) in all jurisdictions according to RAW_DATA.
  • In Australia check TGA/ARTG entries and PBS status at the point of prescribing; specific PBS listings and item numbers should be confirmed before dispensing.
  • Telehealth e-scripts are accepted where they meet PBS prescribing requirements.

Dosing Guide (Australian PBS Reference)

Standard Regimens And Escalation

Typical starting and escalation schedule used in clinical practice.

Phase Dose Notes
Start (Mild–Moderate) 5 mg once daily Maintain for 4–6 weeks before considering escalation
Titrate 10 mg once daily Increase after 4–6 weeks if tolerated
Severe Cases 23 mg once daily Consider after ≥3 months on 10 mg; more adverse effects expected
Maximum 23 mg daily Reserved for selected moderate–severe patients

Duration: Chronic therapy continued while clinically beneficial with periodic re-assessment.

Adjustments For Comorbidities

  • No routine dose reduction solely for age; elderly are the main treatment group but require closer monitoring for cardiac effects.
  • Liver impairment: Mild–moderate — no routine adjustment; severe — use with caution.
  • Kidney impairment: No routine dose adjustment recommended but monitor clinical response.
  • Children: Not approved for paediatric use.

Checklist For Dose Decisions:

  • Review cardiac history and ECG where indicated.
  • Assess concurrent bradycardic medicines (eg beta-blockers) before escalation.
  • Evaluate GI bleed risk and current NSAID/antiplatelet use.
  • Monitor weight and appetite, especially after dose increases.

Q&A — “What If I Miss A Dose?”

Q: Missed one dose of donepezil — what to do?

A: Take as soon as you remember unless it’s near the next scheduled dose.

Do NOT double up; contact your pharmacist or GP if unsure.

Interaction Chart: Food, Drinks And Medicines

Food And Drinks (Alcohol, Caffeine, Australian Diet)

  • Alcohol may worsen dizziness, sedation and fall risk; recommend minimising alcohol until tolerability is known.
  • No specific food restrictions with donepezil, but monitor for appetite loss and weight changes.
  • Encourage hydration and balanced meals to reduce GI upset.

Quick Advice:

  • Avoid excess alcohol during the first weeks of treatment.
  • Monitor caffeine intake if insomnia or vivid dreams develop.

Common Drug Conflicts And Clinical Cautions

Key interaction principles to communicate to prescribers and pharmacists.

Drug Class Interaction Clinical Action
Beta-Blockers, Digoxin, Some Calcium-Channel Blockers Additive bradycardia and conduction slowing Monitor pulse; consider ECG before escalation; review doses
NSAIDs, Antiplatelets Increased risk of GI bleeding when combined with cholinesterase inhibitors Review GI history; use gastroprotection if required; monitor for bleeding
Strong Anticholinergics (eg some antihistamines, antimuscarinics) Pharmacodynamic antagonism — may reduce donepezil benefit Minimise anticholinergic burden where possible
CYP2D6 / CYP3A4 Inhibitors (eg ketoconazole, some SSRIs) May increase donepezil plasma levels Monitor tolerability and adverse effects; adjust monitoring frequency

User Reports & Trends (Australian Patient Feedback)

What carers and patients commonly say about treatment with Aricept or generic donepezil.

  • Early gastrointestinal side effects such as nausea and diarrhoea are commonly reported and often settle over weeks.
  • Some patients or carers report improved alertness, attention or slower functional decline with continued use.
  • Sleep disturbances, vivid dreams or changes to sleep patterns are variably described.
  • Concerns about cost and access, especially for higher-dose or non-PBS supplies, appear frequently in forums and pharmacy enquiries.

Common Patient Statements:

  • “They seemed a bit brighter after a few weeks, but the nausea was hard at first.”
  • “We had to monitor their pulse after the dose increase.”
  • “The tablets are fine, but swallowing ODT helped with earlier choking risks.”
  • “Worried about the cost and whether the brand matters.”

Checklist For Clinicians To Collect Feedback:

  • Onset and degree of perceived cognitive benefit (weeks to months).
  • Weight changes or appetite loss since starting treatment.
  • Any falls, syncope or new dizziness.
  • Mood changes, sleep disturbance or vivid dreams.

Pharmacist Guidance:

  • Record and report adverse effects, counsel on gradual titration and symptomatic management of GI effects.
  • Liaise with the GP or specialist for dose changes or consideration of alternatives (rivastigmine, galantamine, memantine).

Access & Purchase Options In Australia

National Pharmacy Chains And Community Access

Where patients commonly obtain aricept and donepezil in Australia.

  • Major retailers such as Chemist Warehouse, Priceline and TerryWhite Chemmart and independent community pharmacies commonly dispense Aricept or generics where listed.
  • Many patients access donepezil as a PBS-subsidised medicine; confirm PBS eligibility at prescribing.
  • Rural patients may face stock delays; community pharmacy networks and dose-administration aids can help with continuity.

Table Placeholder: Chain | Typical Service | PBS Support Indicator

Online Pharmacies, E-Prescriptions And Telehealth

  • Telehealth consultations can generate PBS-eligible prescriptions where clinical criteria are met.
  • Use accredited Australian online pharmacies and verify prescriptions in real time before dispatch.
  • Be cautious of overseas suppliers promising no-prescription sales — donepezil is Rx-only according to RAW_DATA.

Checklist For Secure Online Ordering:

  • Verify Australian Business Number and pharmacist contact details.
  • Confirm TGA/PBS compliance and prescription upload procedure.
  • Check real-time dispensing records and delivery estimates.

Note: In our online pharmacy, aricept is available with a valid prescription and discreet delivery to Australia in 9–21 days.

Mechanism Of Action & Pharmacology (Patient And Clinician Levels)

Simplified Explanation (For Patients And Carers)

How donepezil works, explained plainly.

Donepezil is a cholinesterase inhibitor that increases the availability of acetylcholine in the brain by inhibiting acetylcholinesterase.

This can modestly improve cognition, attention and daily function for some people with Alzheimer’s disease.

  1. INN: Donepezil.
  2. Class: Cholinesterase inhibitor.
  3. ATC: N06DA02.

Clinical Terms (For Clinicians)

  • Symptomatic onset is often within weeks, with maximal measurable benefit potentially taking months.
  • Pharmacokinetics support once-daily oral dosing; formulations include tablets and ODT; transdermal patches are available in other markets.
  • Adverse-event profile is dose-related: GI effects (nausea, diarrhoea), bradycardia, sleep disturbance; monitor vitals and weight.

Indications & Off-Label Uses (Australian Practice)

Approved Indications By TGA (Alzheimer’s Dementia)

  • Indication per international regulatory positions: treatment of mild, moderate and severe Alzheimer’s dementia.
  • Document the diagnosis and treatment goals on the prescription for clinical clarity.
  • Follow the titration schedule described earlier (5→10→23 mg where appropriate).

Off-Label And Limited Uses In Australia

  • Occasionally considered in Lewy body dementia or vascular cognitive impairment, but evidence and risks vary by condition.
  • Specialist advice (geriatrician or neurologist) is recommended before off-label use.

Pros/Cons When Considering Off-Label Use:

  • Pros: Possible cognitive or behavioural benefit in certain neurodegenerative conditions.
  • Cons: Increased risk of syncope or bradycardia in dementia with Lewy bodies (DLB) and variable supporting evidence.

Key Clinical Findings & Evidence Summary

What the evidence shows and how to use it in practice.

  • Donepezil provides modest symptomatic improvements in cognition and global function for many patients with Alzheimer’s disease.
  • It is not disease-modifying; there is no cure effect demonstrated in trials.
  • Higher 23 mg dosing may offer incremental benefit in moderate–severe disease but carries higher rates of GI adverse events and bradycardia.
  • Recent systematic reviews up to mid-2024 support continued use where documented clinical benefit exists; always re-evaluate periodically.

Main Outcomes:

  • Cognition: Small-to-moderate symptomatic benefit in some patients.
  • Function: Possible slowing of decline in daily activities for selected patients.
  • Behaviour: Mixed results; individual response varies.
  • Safety: GI side effects common; monitor for bradycardia, falls and weight loss.

Alternatives Matrix And PBS-Listed Comparisons

PBS Alternatives Comparison Table

Drug Class Formulations PBS Status Key Pros/Cons
Rivastigmine (Exelon) Cholinesterase Inhibitor Capsule, Patch Varies — check PBS Patch reduces GI AEs for some; requires different titration
Galantamine (Reminyl) Cholinesterase Inhibitor Tablet, Oral Solution Varies — check PBS Alternative cholinesterase inhibitor; hepatic metabolism considerations
Memantine (Namenda) NMDA Antagonist Tablet, Liquid Varies — check PBS Used in moderate–severe disease; often combined with cholinesterase inhibitor

Pros And Cons Checklist (Clinician Selection)

  • Target cognitive stage: mild vs moderate vs severe guides initial choice.
  • Tolerability: consider patch (rivastigmine) where GI adverse effects limit oral agents.
  • Comorbidities: cardiac conduction disease and COPD inform safe selection.
  • Administration preferences: ODTs or patches may help with swallowing or adherence.
  • Consider PBS cost and patient concession eligibility when making the choice.

Practical Note: Rivastigmine patch can reduce GI adverse effects for some patients, and memantine is commonly used in moderate–severe disease, sometimes in combination with a cholinesterase inhibitor.

Common Questions From Australian Pharmacy Consultations

Short pharmacist responses for typical questions at the pharmacy counter.

  • What are the side effects? Commonly nausea, diarrhoea, appetite loss, vivid dreams, dizziness; monitor pulse for bradycardia.
  • Will it stop my loved one’s dementia? It can provide modest symptomatic benefit for some but is not a cure or disease-modifying treatment.
  • Is it covered by PBS? Many formulations are PBS-listed or available as subsidised generics — confirm current PBS item numbers at prescribing time.
  • Can we switch brands? Generic substitutions are commonly used; discuss any concerns about tolerability or formulation with the GP or specialist.

When To Escalate To GP/Geriatrician:

  • Syncope, unexplained bradycardia or significant weight loss.
  • New or worsening falls, severe GI upset or seizure activity.
  • Questions about long-term benefit or consideration of alternative agents.

Micro-FAQ For Clinic Handouts:

  • Monitoring schedule: review after 4–6 weeks for titration decisions.
  • Report urgent issues: fainting, severe vomiting or breathing problems.
  • Medication review: reconcile over-the-counter anticholinergics and NSAID use.

Price & Access Comparison (Pharmacies, PBS, Online)

Comparison Table — Pharmacy/Source, Price Range, PBS Subsidy

Source Typical Price (Non-PBS Range) PBS Subsidy Prescription Requirement
Chemist Warehouse Varies by brand and pack size Often PBS-subsidised where eligible Rx only
Priceline Varies Check PBS listing at dispensing Rx only
TerryWhite Chemmart Varies PBS support common for chronic prescriptions Rx only
Independent Pharmacy Varies PBS subsidy likely if criteria met Rx only
Accredited Online Pharmacy Varies Can dispense PBS scripts if criteria met Rx only

Many patients rely on PBS subsidies and concession pricing; private prescriptions will vary and can be price-sensitive.

Access Checklist — Rural Vs Urban Availability, Repeat Dispensing

  • Confirm stock before travel and plan repeats ahead of time.
  • Use dose administration aids or community nursing support for adherence in rural patients.
  • Enrol eligible patients in repeat dispensing where available to reduce pharmacy visits.

Registration & Regulation (TGA And PBS Practicalities)

TGA Approval And Prescribing Rules

  • Donepezil formulations are regulated by national regulators; pharmacists should verify current ARTG entries and product labels.
  • Originator manufacturer listed in RAW_DATA is Eisai; multiple generic suppliers also supply donepezil globally.
  • Report suspected adverse events to the TGA via standard reporting channels.

PBS Subsidy Details And Prescriber Obligations

  • PBS listing and authority requirements can vary by formulation and dose, for example escalation to 23 mg may need specific authority — confirm current PBS rules before prescribing.
  • Prescribers must meet PBS criteria; pharmacists should confirm item number, authority requirements and patient concession status at dispensing.

PBS Dispensing Checklist:

  • Check PBS item number and authority if required.
  • Confirm patient concession status and eligible repeats.
  • Document prescription and ensure correct labelling and counselling.

Storage, Handling And Supply Chain (Australian Climate)

Household Storage Guidance

  • Store donepezil tablets at room temperature, 15–30°C (59–86°F).
  • Protect from moisture and excessive heat; avoid storage in bathrooms or cars, especially in hot Australian summers.
  • Keep in original packaging until use and out of reach of children.

Patient Checklist:

  • Choose a stable, cool storage spot away from direct sunlight and humidity.
  • Monitor tablet appearance and discard out-of-date supplies safely.

Pharmacy Cold-Chain And Handling Notes

  • No cold-chain is required for tablets or ODT formulations.
  • Patches may have specific storage instructions from the supplier; follow manufacturer guidance where applicable.
  • Implement SOPs for stock rotation and timely rural replenishment to avoid interruptions.
Formulation Storage Temp Handling Note
Tablets (5/10/23 mg) 15–30°C Protect from moisture; no cold-chain
ODT 5/10 mg 15–30°C Keep in original blister until use
Transdermal Patch (Adlarity) Refer to supplier Follow manufacturer storage instructions

Guidelines For Proper Use: Pharmacist Counselling & PBS/National Advice

Australian Pharmacist Counselling Style (Practical Script)

Use this script to guide a short counselling session at dispense.

  • Explain the indication and set realistic goals: symptom management, not a cure.
  • Describe the start and titration schedule: begin 5 mg daily, review in 4–6 weeks for possible increase to 10 mg.
  • List common side effects and red flags: severe vomiting, fainting or marked bradycardia require urgent review.
  • Adherence tips: take at the same time each day and do not double doses if one is missed.
  • PBS/dispensing points: confirm repeats, concession card and authority requirements if any.

Counselling Session Checklist:

  • Confirm patient identity and medication history including OTC medicines.
  • Record baseline pulse and blood pressure or ensure GP has done so.
  • Provide adverse-event reporting pathway and follow-up timeframe (4–6 weeks).

Patient Advice From PBS And National Health Bodies

  • Encourage patients and carers to review PBS fact sheets and resources from NPS MedicineWise and TGA safety communications.
  • Document informed consent for off-label uses and liaise with specialists for complex cases.

Final Checklist For Ongoing Care:

  • Periodic cognitive review and documentation of benefit.
  • Regular weight and fall monitoring, and pulse checks after dose changes.
  • Medication reconciliation every 3–6 months to reduce anticholinergic burden.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9–14 days
Melbourne Victoria 9–14 days
Brisbane Queensland 9–14 days
Perth Western Australia 9–14 days
Adelaide South Australia 9–14 days
Canberra Australian Capital Territory 9–14 days
Hobart Tasmania 9–14 days
Darwin Northern Territory 9–14 days
Gold Coast Queensland 14–21 days
Newcastle New South Wales 14–21 days
Wollongong New South Wales 14–21 days
Geelong Victoria 14–21 days
Cairns Queensland 14–21 days
Townsville Queensland 14–21 days

Related products